Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formula AX is a full-spectrum cannabinoid formulation developed by Endourage for the treatment of anxiety. It is a botanical drug candidate composed of hemp-derived phytocannabinoids, including cannabidiol (CBD) and cannabigerol (CBG), combined with therapeutic terpenes in an organic coconut-derived MCT oil suspension. Administered as sublingual drops, Formula AX targets the endocannabinoid system to regulate cellular homeostasis and mitigate symptoms of anxiety. The formulation is being developed under the FDA's Botanical Drug Path and is currently undergoing early-stage clinical evaluation, including case studies and human trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Formula AX.